The human dopamine transporter (DAT1) gene contains a variable number of tandem repeats (VNTR) in its 3Ј-untranslated region (UTR). The linkage and association between the VNTR polymorphism of DAT1 and various neuropsychiatric disorders have been reported. We have determined the genomic structure of DAT1 genes containing 7-, 9-, 10-, and 11-repeat alleles and examined the effect of VNTR polymorphism in the 3Ј-UTR region of DAT1 on gene expression using the luciferase reporter system in COS-7 cells. Luciferase expression was significantly higher when the 3Ј-UTR of the DAT1 gene contained the 10-repeat allele than when it contained the 7-or 9-repeat alleles. This suggests that VNTR polymorphism affects the expression of the dopamine transporter. The Pharmacogenomics Journal (2001) 1, 152-156.
Dopaminergic brain systems play important roles since dopamine is the major neurotransmitter of the nigrostriatal system and is involved in the control of motor function, cognition and affect. 1 The human dopamine transporter (DAT1) is a member of the sodium and chloride-dependent neurotransmitter transporter family and contains 12 transmembrane domains. 2 The dopamine transporter (DAT) terminates the synaptic transmission by the rapid and specific reuptake of dopamine into the presynaptic nerve terminals. 1, 3, 4 Psychostimulants, such as cocaine and amphetamine, are known to bind the dopamine transporter and inhibit dopamine reuptake. 5 In DAT knockout mice, dopamine clearance is prolonged and the mice show spontaneous hyperactivity. 6 The reduction in dopamine reuptake results in adaptive changes such as a decreased content of dopamine in presynaptic terminals, significant downregulation of D1 and D2 receptor expression, and a loss of tyrosine hydroxylase.
A 40-bp variable number of tandem repeat (VNTR) polymorphism is found in the 3Ј-untranslated region (3Ј-UTR) of the DAT1 gene. 7, 8 Several groups have studied the association between the VNTR polymorphism and some neuropsychiatric disorders, such as attention-deficit hyperactivity disorder (ADHD), 9 Parkinson's disease, 10, 11 alcoholism, [12] [13] [14] and schizophrenia, [15] [16] [17] which are thought to be related to dopaminergic neurons. However, the relationship between the DAT1 gene and these disorders remains unclear because some studies have reported no association between the VNTR polymorphism and these disorders.
Since the polymorphic site lies outside the open reading frame of the DAT, the VNTR polymorphism cannot affect the protein structure. But the VNTR polymorphism may affect the expression level of DAT by modulating the structure or degradation of mRNA. Lesch et al reported that a 44-bp VNTR polymorphism in the promotor region of the serotonin transporter gene affects expression of the gene. 18 In this study, we have investigated the effect of the VNTR polymorphism in the 3Ј-UTR region of the human DAT1 gene on gene expression using the reporter system. First, we analyzed the sequences of DAT1 genes containing 7-, 9-, 10-, and 11-repeat alleles in the 3Ј-UTR from the genomic DNA of several individuals. The sequence of the 10-repeat allele has been reported, but the 7-, 9-, and 11-repeat ones have not previously been determined. We determined the genomic structure of the 7-, 9-, 10-, and 11-repeat alleles and identified nine types of repeat unit, (A)-(I). Each repeat unit is different from the other units and contains two to five nucleotide substitutions. Repeat unit type (F) exceptionally contains 45 bp in which five nucleotides, CCGGA, are repeated. We found the 7-and 9-repeat alleles to have a novel repeat unit type (I), which has five nucleotide substitutions from type (A) (Figure 1) .
To examine the effect of the 3Ј-UTR on DAT1 gene expression, we constructed luciferase-hDAT exon 15 fusion vectors. Exon 15 of DAT1 contains a complete 3Ј-UTR (stop codon, VNTR and polyadenylation signal), and exon 15 containing 7-, 9-, and 10-repeats were inserted downstream of the luciferase (pSecDK-luc-hDAT-exon15-7r, -9r, and -10r, respectively). We have transiently transfected pSecDK-luchDAT-exon15 fusion vectors into COS-7 cells and measured the luciferase activity ( Figure 2) . The luciferase expression level of COS-7 cells transfected with pSecDK-luc-hDATexon15-10r is significantly greater than that of COS-7 cells transfected with pSecDK-luc-hDAT-exon15-7r and -9r ( Figure 2b ; ANOVA followed by Scheffe post-hoc analysis: F(2,24) = 17.3, P Ͻ 0.001). And the luciferase expression of the positive control pSecDK-luc, which contains the bovine growth hormone polyadenylation signal, is much greater than that of any other fusion vector. The relative luciferase activities are 0.247 (7-repeat), 0.266 (9-repeat) and 0.319 (10-repeat), respectively, compared with the positive control. A 22.7% (7-repeat) or 29.2% (9-repeat) reduction of the activity was observed as compared with that of the 10-repeat. We also observed the same tendency using human glioblastoma A172 cells which express DAT1 naturally (data not shown).
The study of DAT knockout mice suggested that the expression of the DAT1 gene is important in controlling synaptic dopamine levels. Homozygous DAT knockout mice show many adaptive changes such as a decreased content of dopamine in presynaptic terminals, significant downregulations of preproenkephalin A, D1 and D2 receptor mRNA, and a loss of tyrosine hydroxylase, while heterozygotes display intermediate values. 6 These findings indicate that DAT is important for the maintenance of dopaminergic neurotransmission, and that changes in the DAT expression level produce profound changes in dopaminergic pathways.
In this study, we have shown that the VNTR polymorphism in the 3Ј-UTR region of the DAT1 gene affects gene expression, and that the expression level is largest when the 3Ј-UTR contains the 10-repeat allele, suggesting that the expression of DAT may depend on the DAT1 genotype and is possibly higher in the brains of individuals with the 10-repeat allele. It has been reported that the macaque monkey has the similar VNTR polymorphism in the 3Ј-UTR region www.nature.com/tpj of the DAT1 gene. This suggests that these effects observed in both COS and A172 cells are thought to be conserved among higher species.
Our in vitro results do not necessarily reflect the in vivo situation. Joensson et al failed to show a relationship between DAT1 polymorphism and CSF metabolite (homovanillic acid) level. 19 The difference in DAT1 gene expression, which is due to the VNTR polymorphism, may have some effect on the synaptic transmission of dopamine. A single photon emission computed tomography (SPECT) study of Heinz et al suggested that homozygous individuals have a higher DAT availability compared with the 9-repeat/10-repeat heterozygous. 20 This finding appears to be consistent with our results. However, Jacobsen et al reported the opposite results that 10/10 homozygous had a reduction of DAT protein compared with those having 9/9 and 9/10. 21 The difference in these two reports may be attributed to the differences in subject groups, or previous drug exposure as Jacobsen suggested. The other SPECT study also suggested that DAT1 increased in human brain after alcohol withdrawal. 22 Therefore it is highly possible that the effect of the VNTR may appear in early age having no drug experience. In fact, an association between ADHD and the DAT1 10-repeat allele has been reported. 9 However it remains unclear how the VNTR polymorphism affects gene expression.
In this work, we investigated the effects of 9-repeat and 10-repeat alleles on the expression of the DAT1 gene in addition to the newly-found 7-repeat allele. The effects of the rarer repeat on the expression of the DAT1 gene should be tested in future. In addition, we could not confirm the recent finding of Ueno. 23 All the genomic DNA of individuals we sequenced were shown to be A at 2319 position.
MATERIALS AND METHODS
Analysis of the VNTR of the DAT1 Gene from Genomic DNA Genomic DNA was extracted from peripheral blood leukocytes according to the standard method. PCR amplification of the VNTR of the human DAT1 gene (hDAT) from genomic DNA was accomplished with the primers T3-5Long and T7-3aLong. 2 PCR products were cloned into pUC19, and sequence analysis was performed on both strands using a Thermo Sequenase fluorescent labelled primer cycle sequencing kit (Amersham Pharmacia Biotech, Bucks, UK) according to the manufacturer's instructions.
Construction of Luciferase-hDAT Exon15 Vectors
PCR amplification of exon15 of the DAT1 gene was accomplished with the oligonucleotide primers hDAT-ex15S (5Ј-CCACTGGCTCGAG GTGTAGAGG-3Ј) and hDATex15AS (5Ј-CCACGCGACTCGAGACAAGGAG-3Ј), which were designed to contain restriction enzyme sites. Reactions were carried out in a total volume of 20 l containing 0.5 ϫ GC Buffer I, 0.5 ϫ GC Buffer II, 0.4 mM dNTPs, 0.5 U of LA-taq polymerase (TAKARA), primers at 0.5 mM and 40 ng genomic DNA solution. Each reaction began with a single denaturation step at 96°C for 4 min, followed by 30 cycles of 30 s at 96°C, 30 s at 60°C, 3 min at 72°C. Reactions were completed with one step at 72°C for 10 min. The PCR product contains the complete 3Ј-UTR region of the DAT1 gene (stop codon, the VNTR and poly A signal). PCR products containing 7, 9, and 10 repeats were cloned into pGEM Teasy vector (Promega), and the sequences were determined (pGEM-hDAT-exon15-7r, pGEM-hDAT-exon15-9r, and pGEM-hDAT-exon15-10r, respectively).
The pSecDK-luc was constructed by cloning luciferase into pSecDK, which was digested with BamHI and XhoI. The pSecDK is a pSecTagA (Invitrogen) deleted Ig-chain leader sequence. 24 pGEM-hDAT-exon15-7r, -9r, and -10r were digested with XhoI, and fragments of about 2-kb DNA fragments were subcloned into pSecDK-luc to obtain pSecDKluc-hDAT-exon15-7r, -9r, and -10r, respectively.
Luciferase Assay
The luciferase expression vectors were transiently transfected into COS-7 cells by the electroporation method. 25 www.nature.com/tpj This assay was independently done nine times, using the same amounts of the vector. After incubation at 37°C for 60 h, the transfected cells were harvested and luciferase activity was measured using the Luciferase Assay System (Promega). The data were analyzed by analysis of variance (ANOVA) followed by Scheffe post-hoc analyses.
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